Do Patients Understand The Term ‘Median’ In Advertising? US FDA Aims To Find Out
In first Rx advertising research project of 2023, FDA will survey consumers on how they interpret quantitative claims in DTC ads. Lilly questions design of another study examining relative importance of product information, citing FDA comments at tanezumab advisory committee.
You may also be interested in...
National Advertising Division refers Gilead’s challenge of ViiV’s advertisements to the FDA and FTC after ViiV declines to participate in its review. Gilead says the ads claim Dovato is superior to its HIV drug Biktarvy, while ViiV suggests a review would amount to second-guessing the FDA.
However, similar claim in materials directed at health care providers need not be discontinued, National Advertising Division says in challenge brought by Lilly; NAD decisions in Rx promotion disputes are rare, but voluntary resolution process could become more appealing to pharma firms.
US FDA study is to examine the relative importance of product information, such as efficacy, risk and patient preference claims, in the treatment preferences of consumers and physicians.